1.08
-0.01 (-0.92%)
Market Trend
| Short Term | Medium Term | ||
| Industry | Biotechnology (US) | Mixed | Bearish |
| Biotechnology (Global) | Mixed | Bearish | |
| Stock | Adaptimmune Therapeutics plc | Bullish | Bearish |
Stockmoo Score
|
Adaptimmune Therapeutics PLC is a clinical-stage biopharmaceutical company. It focused on providing novel cell therapies to patients, particularly in solid tumors. It has developed a comprehensive proprietary platform that enables it to identify cancer targets, find and genetically engineer T-cell receptors, and produce TCR therapeutic candidates for administration to patients. Its programs include MAGE-A4 SPEAR T-cell therapy, NY-ESO SPEAR T-cell, CD70 and others for multiple cancer types. |
|
| Sector | Healthcare |
| Industry | Biotechnology |
| 52 Weeks Range | ||
| Median | 4.00 (270.37%) | |
| Total | 1 Buy | |
| Firm | Date | Target Price | Call | Price @ Call |
|---|---|---|---|---|
| HC Wainwright & Co. | 13 Aug 2024 | 4.00 (270.37%) | Buy | 1.05 |
| 30 Jul 2024 | 4.00 (270.37%) | Buy | 1.30 |
No data within this time range.
| Date | Type | Details |
|---|---|---|
| 28 Aug 2024 | Announcement | Adaptimmune to Participate in Two Bank Conferences this September |
| 12 Aug 2024 | Announcement | Adaptimmune Reports Q2 2024 Financial and Business Updates |
| 05 Aug 2024 | Announcement | Adaptimmune to Report Q2 2024 Financial and Business Updates on Monday, August 12, 2024 |
| 01 Aug 2024 | Announcement | Adaptimmune Receives U.S. FDA Accelerated Approval of TECELRA® (afamitresgene autoleucel), the First Approved Engineered Cell Therapy for a Solid Tumor |
The support, resistance and trendline levels presented has been generated by an artificial intelligence (AI) model and should be interpreted with caution.
Portfolio
| Realized Profit | - |
| Unrealized Profit | - |
| Dividend Received 2024 | - |
| Total Profit | - |
| Avg. Return | - |
| Quantity (Buy) | - |
| Avg. Price (Buy) | - |
| Quantity (Sold) | - |
| Avg. Price (Sold) | - |